CeriBell (NASDAQ:CBLL) Receives $32.60 Average Price Target from Analysts

Shares of CeriBell (NASDAQ:CBLL) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $32.60.

CBLL has been the subject of several recent analyst reports. JPMorgan Chase & Co. began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price for the company. Canaccord Genuity Group started coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. TD Cowen boosted their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group increased their price objective on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Bank of America started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company.

CeriBell Price Performance

Shares of CBLL stock opened at $26.45 on Wednesday. CeriBell has a 1 year low of $23.00 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. As a group, analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.